Exploring the Therapeutic Potential of Emerging Therapies in Pulmonary Fibrosis - CME

CME

Title: Exploring the Therapeutic Potential of Emerging Therapies in Pulmonary Fibrosis

Link

Description: Fibrosing interstitial lung diseases (ILD) encompass a range of disorders such as idiopathic pulmonary fibrosis and systemic autoimmune rheumatic disease-associated ILD. This heterogeneous group of disorders includes a subset of patients who experience progressive pulmonary fibrosis (PPF) with declines in lung function over time. This progression is often accompanied by worsening symptoms, such as dyspnea, cough, and fatigue, and can lead to high rates of hospitalization and death. Effective management of PPF necessitates a multidisciplinary approach, demanding proficiency in the most up-to-date diagnostic techniques, therapeutic interventions, and supportive care strategies. Treatment guidelines recommend antifibrotic agents and supportive care strategies such as oxygen therapy and pulmonary rehabilitation. Agents with novel antifibrotic and anti-inflammatory mechanisms of action are now available with additional approaches on the horizon; yet evidence indicates that use of antifibrotic therapies is suboptimal with many patients receiving treatment late in disease progression. Dive into this unique educational experience with CrossMED™! This engaging activity combines clue-based crosswords with word games to test your knowledge. Then, immerse yourself in expert videos, resources, and supporting data to increase your proficiency with the integration of novel therapies for PPF. Support better outcomes for your patients through this fun and engaging learning opportunity today!

Target Audience: This activity is intended for pulmonologists and advanced practice providers in pulmonology settings.

Learning Objectives

Discuss unmet needs associated with standard of care for treating pulmonary fibrosis
Evaluate current and emerging antifibrotic therapies for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) in terms of efficacy, adverse events (AEs), and patient suitability
Identify opportunities to integrate emerging pharmacologic interventions into patient-centered care plans to alleviate the clinical burden associated with fibrosing ILDs

Estimated Duration: 75 minutes

Delivery Mode: Online

Format: Online Learning

Specialties: Pulmonology

Keywords: autoimmune rheumatic disease

Disclosures and Disclaimers: The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s). This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Accredited Providers

Rush University Medical Center
Academy for Continued Healthcare Learning (ACHL)

Commercial Support

Boehringer Ingelheim Pharmaceuticals, Inc

Activity Expiration Date: April 10, 2027

Credit Information

Credit Type	Units / Unit Type	Board
AMA PRA Category 1 Credit	1.25 Credits	ACCME- Accreditation Council for Continuing Medical Education